Money

Found 79,792 articles

• Prelude Therapeutics Announces Launch of Proposed Public Offering - May 17, 2023

  5/17/2023

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock.

• Cabaletta Bio Announces Proposed Public Offering of Common Stock - May 17, 2023

  5/17/2023

  Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of its common stock.

• Pfizer Prices $31,000,000,000 Debt Offering

  5/17/2023

  Pfizer Inc. announced the pricing of a debt offering consisting of eight tranches of notes.

• Philips announces exchange ratio for 2022 dividend

  5/17/2023

  Royal Philips announced that the exchange ratio for the dividend for the year 2022 is 1 new common share for every 22.3906 existing common shares.

• Invitation to Immunovia's Q1 presentation

  5/17/2023

  Immunovia will publish its first quarter 2023 results on May 23, 2023 at 8:30 am CET.

• Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

  5/17/2023

  Bloom Burton & Co. Inc. announces that, today, it and its affiliate acquired 1,453,070 common shares (Shares) and 6,636,734 compensation options (Compensation Options) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a short form prospectus dated May 9, 2023.

• EDAP Announces First Quarter 2023 Financial Results

  5/17/2023

  EDAP TMS SA, the global leader in robotic energy-based therapies, announced unaudited financial results for the first quarter ended March 31, 2023.

• Inclusion of Recbio In the MSCI China Small Cap Index

  5/17/2023

  Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes on May 12, 2023, and the Company has been selected as a constituent of the MSCI China Small Cap Index, with effect from the close of market on May 31, 2023.

• RaySearch Laboratories: Interim report January 1 - March 31, 2023

  5/17/2023

  CEO Johan Löf and CFO Henrik Bergentoft will present RaySearch's interim report for January-March 2023 at a webcast to be held in English on Wednesday, May 17, 2023 at 10:00-10:30 a.m. CEST.

• Mantra pharma maintains steady growth

  5/17/2023

  Mantra Pharma maintains impressive growth completing 39 product launches, including all strengths, in the past 16 months.

• Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy

  5/17/2023

  Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that it has closed an equity offering, issuing a total of 110 million equity securities for gross proceeds of $55 million (the "Offering").

• Biotricity Reaches $13M Revenue Run Rate in April 2023 on Accelerating Growth

  5/16/2023

  Biotricity Inc. reported that it reached a record $13 million annualized revenue run rate in April -- further extending its growth by over eight percent from the $12 million run rate it announced for March 2023.

• Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases

  5/16/2023

  Ray Therapeutics today announced an upsized and oversubscribed $100M Series A financing round led by Novo Holdings A/S, and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and existing investor 4BIO Capital.

• Ensoma Closes Series B Extension, Bringing Total Round to $135 Million

  5/16/2023

  Ensoma announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million.

• Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer

  5/16/2023

  Boundless Bio today announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital.

• EPI’s Pulvinar Neuro is Awarded $3 Million NIH Grant for Transcranial Stimulation Research

  5/16/2023

  Pulvinar Neuro was awarded a grant from the National Institutes of Health (NIH) to further its research in transcranial stimulation (TCS) as a potential treatment for psychiatric disorders.

• ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders - May 16, 2023

  5/16/2023

  ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced that its 2023 Annual Meeting of Stockholders will be conducted virtually.

• Pressure BioSciences, Inc. Q1 2023 Financial Results Achieve All-Time Quarterly Record

  5/16/2023

  Pressure BioSciences, Inc. reported that record quarterly financial results for any fiscal quarter was achieved in the first quarter ended March 31, 2023.

• International Isotopes Inc. Announces Financial Results for the First Quarter 2023

  5/16/2023

  International Isotopes Inc. is pleased to announce its financial results for the three months ended March 31, 2023.

• Upkara Secures $9M to Fuel Growth and Bring Game-Changing Biopreservation Technology to Market

  5/16/2023

  Upkara announced that it has secured $9 million in Series A funding, including additional investment from prominent businessman and philanthropist, Bill Parfet, along with industry veteran, Paul Meister, former Chairman of Thermo Fisher Scientific.